Neurology · 2007 · 54 citations · 43 references
Life SciencesBiochemistryNeuroscienceDementiaNeurochemistryNeurodegenerationAlzheimer DiseaseCognitive ImpairmentDementia BiomarkersNeurodegenerative DiseasesNeurodegenerative DisordersTau PathologyAlzheimer Disease DementiaAlzheimer Disease ProgressionAlzheimer Disease Tau PathologyBrain RegionsCognitive Impairment AssociationsMild Cognitive Impairment ProgressionProdromal Dementia DetectionTau Protein Biomarkers
OBJECTIVE: Mild cognitive impairment, hypothesized to be prodromal Alzheimer disease (AD), shows abundant senile plaques and neurofibrillary tangles, but its biochemical correlates remain undefined. METHODS: Biochemical profiles of Abeta, tau, alpha-synuclein, and oxidative pathologies were characterized in middle frontal gyrus, inferior parietal cortex, and entorhinal cortex in postmortem frozen brains from subjects diagnosed antemortem with no cognitive impairment, mild cognitive impairment, or AD. RESULTS: Insoluble Abeta and tau, as well as tissue isoprostanes, from each brain region analyzed did not correlate with the clinical diagnosis proximate to death, but insoluble Abeta and 8,12-iso-iPF(2alpha)-VI levels from gray matter of all brain regions correlated strongly with the burden of AD pathology, whereas insoluble tau did not. CONCLUSIONS: The biochemical alterations in cortical tau, Abeta, and isoprostane do not reflect the onset of clinical dementia.
43
Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 86.9K citations
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Suzanne S. Mirra, Albert Heyman, Daniel W. McKeel et al. · Neurology · 1991 · 5.1K citations
Gustavo C. Román, T. K. Tatemichi, Timo Erkinjuntti et al. · Neurology · 1993 · 4.9K citations
Medicine, Neurology, Neuroscience +17